Covid-19 and radiotherapy: a systematic review after 2 years of pandemic
Authors:
- 23 July 2022
- journal article
- review article
- Published by Springer Nature in Clinical and Translational Imaging
- Vol. 10 (6) , 611-630
Abstract
Introduction Following the Covid-19 pandemic spread, changes in clinical practice were necessary to limit the pandemic diffusion. Also, oncological practice has undergone changes with radiotherapy (RT) treatments playing a key role. Although several experiences have been published, the aim of this review is to summarize the current evidence after 2 years of pandemic to provide useful conclusions for clinicians. Methods A Pubmed/MEDLINE and Embase systematic review was conducted. The search strategy was “Covid AND Radiotherapy” and only original articles in the English language were considered. Results A total of 2.733 papers were obtained using the mentioned search strategy. After the complete selection process, a total of 281 papers were considered eligible for the analysis of the results. Discussion RT has played a key role in Covid-19 pandemic as it has proved more resilient than surgery and chemotherapy. The impact of the accelerated use of hypofractionated RT and telemedicine will make these strategies central also in the post-pandemic period.Keywords
This publication has 309 references indexed in Scilit:
- Clinical Characteristics of Coronavirus Disease 2019 in ChinaNew England Journal of Medicine, 2020
- Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in ChinaJAMA, 2020
- Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive studyThe Lancet Infectious Diseases, 2020
- Cancer patients in SARS-CoV-2 infection: a nationwide analysis in ChinaThe Lancet Oncology, 2020
- Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor bindingThe Lancet, 2020
- Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trialThe Lancet, 2019
- Radiomics: Principles and radiotherapy applicationsCritical Reviews in Oncology/Hematology, 2019
- The future of personalised radiotherapy for head and neck cancerThe Lancet Oncology, 2017
- The need for radiotherapy in Europe in 2020: Not only data but also a cancer planActa Oncologica, 2015
- Radiotherapy: the last 25 yearsCancer Treatment Reviews, 1999